Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia.
Anemia
Enzyme replacement treatment
Gaucher disease
Neuronopathic gaucher disease
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
05
07
2018
accepted:
12
11
2018
revised:
11
11
2018
pubmed:
21
11
2018
medline:
7
3
2019
entrez:
21
11
2018
Statut:
ppublish
Résumé
Gaucher disease (GD) is caused by a hereditary deficiency of glucocerebrosidase, resulting in accumulation of glucosylceramide and potentially manifesting as hepatosplenomegaly. We report the case of a 15-month-old boy with chronic neuronopathic GD. The patient had prolonged anemia despite continued iron supplementation for 3 months. White blood count (WBC), hemoglobin (Hb), platelet count, and corrected reticulocyte count were 3,300 /µL, 8.7 g/dL, 90,000 /µL, and 0.55, respectively. The patient had microcytic hypochromic anemia with mildly elevated ferritin. Physical examination revealed hepatosplenomegaly. Bone-marrow aspiration showed sheets of Gaucher cells. Glucocerebrosidase activity in monocytes was significantly lower than normal. Genetic analysis revealed a homozygous L444P mutation of GBA, and he was diagnosed with type 1 GD. Enzyme replacement treatment (ERT) consisting of imiglucerase was initiated and was effective; WBC, Hb, and platelet count gradually normalized and the hepatosplenomegaly improved. However, when the patient entered elementary school, he showed mild impaired cognitive function, and supranuclear gaze palsy occurred the same year. He was ultimately diagnosed with type 3 GD and continued ERT. Pediatric hemato-oncologists should be aware of GD, especially when patients exhibit anemia refractory to iron therapy, radiologic bone deformity, neurologic signs or symptoms, and growth retardation.
Identifiants
pubmed: 30456712
doi: 10.1007/s12185-018-2559-3
pii: 10.1007/s12185-018-2559-3
doi:
Substances chimiques
Hemoglobins
0
Glucosylceramidase
EC 3.2.1.45
imiglucerase
Q6U6J48BWY
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
361-365Commentaires et corrections
Type : ErratumIn
Références
Hum Genet. 1999 Jul-Aug;105(1-2):120-6
pubmed: 10480365
PLoS Med. 2004 Nov;1(2):e21
pubmed: 15578103
Hematology. 2005 Apr;10(2):151-6
pubmed: 16019462
Arch Pediatr Adolesc Med. 2006 Jun;160(6):603-8
pubmed: 16754822
Am J Hematol. 2007 Aug;82(8):697-701
pubmed: 17492645
Blood Cells Mol Dis. 2011 Jan 15;46(1):11-4
pubmed: 20729108
Korean J Pediatr. 2012 Feb;55(2):48-53
pubmed: 22375149
Blood Cells Mol Dis. 2013 Mar;50(3):212-7
pubmed: 23219328
Pediatr Hematol Oncol. 2013 Mar;30(2):61-70
pubmed: 23363328
Br J Haematol. 2014 May;165(4):427-40
pubmed: 24588457
Pediatr Blood Cancer. 2014 Nov;61(11):1905-9
pubmed: 25131373
N Engl J Med. 2014 Oct 2;371(14):1324-31
pubmed: 25271605
Am Fam Physician. 2016 Feb 15;93(4):270-8
pubmed: 26926814
Mol Genet Metab. 2017 Jan - Feb;120(1-2):47-56
pubmed: 28040394
Blood Res. 2016 Dec;51(4):268-273
pubmed: 28090490
Eur J Pediatr. 1982 Nov;139(3):187-91
pubmed: 7160406
JAMA. 1999 Jan 20;281(3):249-54
pubmed: 9918480